reviral company logo

ReViral – Innovative therapies for viral diseases

ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.

The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion which will enter clinical trials in H2/2016.


Upcoming Events

2016 Bio-International Convention
June 6th-9th 2016
San Francisco

 

Latest News
Mar 30, 2016
ReViral Scientific Advisory Board meeting
30th March, 2016, London ReViral held its first Scientific Advisory...
Jan 1, 2016
Dr Elaine Thomas joins the ReViral team as Head of Virology
Terms & Conditions
Privacy Policy
© Copyright ReViral 2016